Antihormonal drugs can be used to treat hormone-induced cancers, mainly including breast cancer and prostate cancer. According to statistics, in 24, the market size of anti-hormonal drugs for cancer reached 4.8 billion US dollars, and it is estimated that by 214, the market size will be 5.5 billion US dollars, with an average annual growth rate of only .9%. The main reasons for the slow growth of anti-hormonal drugs are as follows: First, the market of anti-hormonal drugs is in a mature and relatively saturated state; Second, some important patented drugs have lost or will soon lose patent protection, which is accompanied by the emergence of generic drugs and their involvement in market competition; Third, the use of chemotherapy is increasing, which will more or less reduce the importance of anti-hormonal drugs.
From the market share of anti-hormone drugs in 24, luteinizing hormone-releasing hormone (LHRH) analogues accounted for 5%; The share of aromatase inhibitors is 23%; The proportion of antiandrogen drugs is 2%; The share of anti-estrogen drugs is 5%; The other 2% are other kinds of anti-hormone drugs, and there is only one product of this kind of drugs at present, that is, AstraZeneca's Faslodex (fulvestrant). It is estimated that between 24 and 214, the sales of LHRH analogues will decrease at an average annual rate of 1.5%, and the anti-androgen drugs will also decrease at an average annual rate of 1.4%. It is predicted that by 214, the market share of these drugs will change as follows: LHRH analogues account for 42%; Aromatase inhibitors accounted for 34%; Antiandrogen drugs accounted for 18%; Antiestrogen drugs accounted for 3%; Faslodex accounts for 3%. Generally speaking, the growth opportunities of anti-hormone drugs are relatively limited, but the upward trend of aromatase inhibitors is obvious and attracts people's attention.
for p>3 years, Tamoxifen, as one of the standard therapeutic drugs for breast cancer, has been a major variety of anti-estrogen drugs. However, the results of several recent clinical trials show that aromatase inhibitors are more effective than tamoxifen in the treatment of breast cancer and less toxic. Therefore, the use of breast cancer drugs is gradually shifting from tamoxifen to aromatase inhibitors.
according to the positive results of several clinical trials (especially the ATAC trial, that is, the comparative trial of anastrozole and tamoxifen alone or in combination), ASCO suggests that postmenopausal breast cancer patients with hormone receptor positive should take aromatase inhibitors as an adjuvant therapy while taking tamoxifen for initial or late treatment.
this proposal of p>ASCO is expected to promote the use and sale of aromatase inhibitors. In 24, the sales of aromatase inhibitors were $1.1 billion. It is estimated that by 21, its sales will reach the peak value of $2.2 billion. Since then, the sales of aromatase inhibitors will also fall back, and will be reduced to $1.9 billion in 214. At the same time, the sales of aromatase inhibitors will increase, and the market size of these drugs will decrease from $258 million in 24 to $166 million in 214, with an average annual growth rate of-3.7%.
At present, several comparative clinical trials of various aromatase inhibitors and tamoxifen have preliminarily shown that aromatase inhibitors have relative advantages. Analysts predict that aromatase inhibitors will eventually replace tamoxifen as a standard anti-hormone drug for the treatment of breast cancer. AstraZeneca's Reninder (Anastrozole), Novartis's Furlong (Letrozole) and Pfizer's Anoxin (Norman Cancer) are generally favored by the industry, and their markets are expected to grow significantly. However, although tamoxifen will lose its status as a standard therapeutic drug, it will still occupy a certain share of the anti-hormone drug market for some time to come. (Xinhua News Agency)